BioMimetic Therapeutics Profit Margin: -1661.78%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMTI Profit Margin Rankings
| Overall | 0th percentile | 4406 of 4439 |
| Sector | 4th percentile | 448 of 471 in Healthcare |
| Industry | 3rd percentile | 63 of 65 in Medical Instruments & Supplies |
BMTI Profit Margin Range, Past 5 Years
| Minimum | -967.53% | Mar 2006 |
| Maximum | -99.05% | Sep 2005 |
| Average |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these BMTI related companies
BMTI News
BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS
Feb 08, 9:25AM Business Wire
Feb 08, 9:25AM Business Wire
Collins Stewart Reiterates a 'Buy' on BioMimetic Therapeutics (BMTI); Positive Pilot Study Offer Another Sizable Opportunity
Feb 07, 11:05AM Street Insider
Feb 07, 11:05AM Street Insider
Morning Movers 02/07: (SATC) (BMTI) (CSTR) (MNI) Higher; (ASTX) (ACHN) (BVSN) Lower
Feb 07, 11:00AM Street Insider
Feb 07, 11:00AM Street Insider
BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings
Feb 06, 4:00PM Business Wire
Feb 06, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 10, 11:00AM Business Wire
Jan 10, 11:00AM Business Wire
Wedbush Downgrades BioMimetic Therapeutics (BMTI) to Neutral, Still See Approval of Augment Bone Graft
Jan 04, 12:18PM Street Insider
Jan 04, 12:18PM Street Insider
$BMTI BioMimetic Therapeutics downgraded to Neutral from Outperform at Wedbush
about 39 days ago by _TheBlackSwan_
about 39 days ago by _TheBlackSwan_
BioMimetic (BMTI) Down as FDA Doesn't Approve Augment Bone Graft PMA in Current Form
Jan 03, 4:19PM Street Insider
Jan 03, 4:19PM Street Insider
BioMimetic (BMTI) Doesn't Get FDA Approval for Augment Bone Graft in Current Form
Jan 03, 4:15PM Street Insider
Jan 03, 4:15PM Street Insider
BioMimetic Therapeutics Announces Approval to Market GEM 21S in the European Union
Jan 03, 4:11PM Benzinga
Jan 03, 4:11PM Benzinga
BioMimetic Therapeutics Announces Approval to Market GEM 21S® in the European Union
Jan 03, 4:11PM Business Wire
Jan 03, 4:11PM Business Wire
BioMimetic Therapeutics Receives Augment Bone Graft PMA Response Letter from FDA
Jan 03, 4:04PM Benzinga
Jan 03, 4:04PM Benzinga
BioMimetic Therapeutics Receives Augment® Bone Graft PMA Response Letter from FDA
Jan 03, 4:04PM Business Wire
Jan 03, 4:04PM Business Wire
$BMTI http://stks.co/1LXu large directional move implied given ideal adx alignment, needs over $3.15 to snowball HT @stt2318
about 73 days ago by traderdigs
about 73 days ago by traderdigs
$BMTI Collins Stewart Starts BioMimetic Therapeutics at Buy http://stks.co/1Euy
about 82 days ago by ACInvestorBlog
about 82 days ago by ACInvestorBlog
$BMTI http://stks.co/1EtQ We are on the verge of a possible breakout in the shares of $BMTI.Upgraded this morning to BUY.PT $7
about 82 days ago by ACInvestorBlog
about 82 days ago by ACInvestorBlog
BioMimetic Therapeutics, Inc. Reports Third Quarter 2011 Earnings Results
Nov 08, 4:00PM Business Wire
Nov 08, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report 2011 Third Quarter Financial Results on November 8
Nov 04, 11:02AM Business Wire
Nov 04, 11:02AM Business Wire
BioMimetic $BMTI receives approval to commercialize Augment(R) Bone Graft in Australia
about 116 days ago by Street_Insider
about 116 days ago by Street_Insider
@ACInvestorBlog How do u feel about $BMTI ATM? Im long @ 2.99. Have any info besides technicals? What do u think breakout will look like?
about 122 days ago by JohnETownsend
about 122 days ago by JohnETownsend
$BMTI http://stks.co/aGq $K line has just crossed on top over $D line indicating buy signal. Nice bottom base here.
about 124 days ago by ACInvestorBlog
about 124 days ago by ACInvestorBlog
Potential upside of 303.4% exists for $BMTI .... lol ... nice post : http://stks.co/XXq
about 128 days ago by ACInvestorBlog
about 128 days ago by ACInvestorBlog
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMTI | 2.13 | -0.10 | -4.48% | 59.73M |
| MOV | 18.85 | 0.00 | 0.00% | 343.64M |
| NOK | 4.96 | -0.11 | -2.17% | 18.58B |
| WDC | 38.57 | -0.62 | -1.58% | 9.02B |
| GG | 45.87 | -0.81 | -1.74% | 37.11B |
| GIB | 20.39 | -0.09 | -0.44% | 4.62B |
| RUE | 26.23 | 0.15 | 0.58% | 641.59M |
| PRX | 36.55 | -0.50 | -1.35% | 1.33B |
| NUE | 44.47 | -0.93 | -2.05% | 14.08B |
| AEM | 34.71 | -0.92 | -2.58% | 5.87B |
